BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33316767)

  • 1. Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response.
    Zou F; Abu-Sbeih H; Ma W; Peng Y; Qiao W; Wang J; Shah AY; Glitza Oliva IC; Piha-Paul SA; Thompson JA; Zhang HC; Thomas AS; Wang Y
    J Natl Compr Canc Netw; 2020 Dec; 19(6):700-708. PubMed ID: 33316767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
    Zou F; Faleck D; Thomas A; Harris J; Satish D; Wang X; Charabaty A; Ernstoff MS; Glitza Oliva IC; Hanauer S; McQuade J; Obeid M; Shah A; Richards DM; Sharon E; Wolchok J; Thompson J; Wang Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34789551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.
    Abu-Sbeih H; Ali FS; Alsaadi D; Jennings J; Luo W; Gong Z; Richards DM; Charabaty A; Wang Y
    J Immunother Cancer; 2018 Dec; 6(1):142. PubMed ID: 30518410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.
    Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y
    J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections.
    Ma W; Gong Z; Abu-Sbeih H; Peng Y; Peng F; Zou F; Charabaty A; Okhuysen PC; McQuade JL; Altan M; Zhang HC; Thomas AS; Wang Y
    Am J Clin Oncol; 2021 Aug; 44(8):402-408. PubMed ID: 34107499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
    Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis.
    Zou F; Wang X; Glitza Oliva IC; McQuade JL; Wang J; Zhang HC; Thompson JA; Thomas AS; Wang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer.
    Liu C; Shatila M; Mathew A; Machado AP; Thomas A; Zhang HC; Thomas AS; Faleck D; Funchain P; Philpott J; Grivas P; Obeid M; Carbonnel F; Wang Y
    J Cancer; 2023; 14(10):1913-1919. PubMed ID: 37476185
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson.
    Wang Y; Abu-Sbeih H; Mao E; Ali N; Ali FS; Qiao W; Lum P; Raju G; Shuttlesworth G; Stroehlein J; Diab A
    J Immunother Cancer; 2018 May; 6(1):37. PubMed ID: 29747688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
    Bonanno L; Lorenzi M; Massa D; De Nuzzo M; Angerilli V; Zingone F; Barberio B; Russi A; Girardi F; Ferro A; Dal Maso A; Frega S; Pasello G; Dei Tos AP; Coppola M; Fassan M; Savarino EV; Guarneri V
    Oncologist; 2024 Jan; 29(1):e118-e130. PubMed ID: 37603442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.
    Abu-Sbeih H; Ali FS; Naqash AR; Owen DH; Patel S; Otterson GA; Kendra K; Ricciuti B; Chiari R; De Giglio A; Sleiman J; Funchain P; Wills B; Zhang J; Naidoo J; Philpott J; Gao J; Subudhi SK; Wang Y
    J Clin Oncol; 2019 Oct; 37(30):2738-2745. PubMed ID: 31163011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis.
    Saji A; Chopra M; Jacob J; Altan M; Alhalabi O; Shah AY; Qiao W; Wang Y; Thomas A
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5841-5852. PubMed ID: 36585982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis.
    Abu-Sbeih H; Ali FS; Luo W; Qiao W; Raju GS; Wang Y
    J Immunother Cancer; 2018 Sep; 6(1):95. PubMed ID: 30253811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways.
    Sleiman J; Brand RM; Pai R; Brand RE; Rhee J; Schwartz M; Davar D
    Clin J Gastroenterol; 2023 Oct; 16(5):680-684. PubMed ID: 37452993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review.
    Gong Z; Wang Y
    JCO Oncol Pract; 2020 Aug; 16(8):453-461. PubMed ID: 32584703
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Vasavada S; Panneerselvam K; Amin R; Varatharajalu K; Okhuysen PC; Oliva ICG; Wang J; Grivas P; Thomas AS; Wang Y
    Ann Gastroenterol; 2022; 35(4):393-399. PubMed ID: 35784625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.
    Wang Y; Abu-Sbeih H; Mao E; Ali N; Qiao W; Trinh VA; Zobniw C; Johnson DH; Samdani R; Lum P; Shuttlesworth G; Blechacz B; Bresalier R; Miller E; Thirumurthi S; Richards D; Raju G; Stroehlein J; Diab A
    Inflamm Bowel Dis; 2018 Jul; 24(8):1695-1705. PubMed ID: 29718308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis.
    Kono M; Shatila M; Xu G; Lu Y; Mathew A; Mohajir W; Varatharajalu K; Qiao W; Thomas AS; Wang Y
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint Inhibitor Colitis With Superimposed Clostridioides difficile Infection.
    Mohammad AW; Kusnik A; Mostafa MR; Tan J; Strapko A
    Cureus; 2023 Apr; 15(4):e37006. PubMed ID: 37139037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?
    Choi K; Abu-Sbeih H; Samdani R; Nogueras Gonzalez G; Raju GS; Richards DM; Gao J; Subudhi S; Stroehlein J; Wang Y
    Inflamm Bowel Dis; 2019 Jan; 25(2):385-393. PubMed ID: 30169584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.